Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis and network meta-regression
Khalil I, Islam MR, Promi SA, Joy AD, Sayed MA, Acharjee D, Al-Shammari AS, Rahman MT, Abrar S, Bin Jamil TS, Taseen M, Biswas S, Mifty SK, Al-Badri SG, Debnath A, Hossain MI, Akter MM
Medicine · 0 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2026-05-15 · Medicine (Baltimore) · vol. 105 · número 20 · pág. e48627
- Editorial
- Wolters Kluwer
- Citado
- 0 citas · más que el 36% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 38 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Paraoxonase enzyme and polymorphisms · Blood Pressure and Hypertension Studies
- Palabras clave
- cholesteryl ester transfer protein inhibitors, CETP inhibitors, evacetrapib, anacetrapib, dalcetrapib, torcetrapib, cardiovascular outcomes, cardiovascular mortality, major adverse cardiovascular events, myocardial infarction, stroke, revascularization, all-cause mortality, lipid-lowering therapy
- MeSH
- humans, cardiovascular diseases, amides, esters, sulfhydryl compounds, oxazolidinones, benzodiazepines, quinolines, anticholesteremic agents, bayes theorem, cholesterol ester transfer proteins, randomized controlled trials as topic, stroke
17 autores
- Ibrahim Khalil🇧🇩 · autor de correspondenciaDhaka Medical College and Hospital
- M Rafiqul Islam🇧🇩Shaheed Suhrawardy Medical College
- Sunjida Amin Promi🇧🇩Chattagram Maa-O-Shishu Hospital Medical College
- Arindam Das Joy🇧🇩Dhaka Medical College and Hospital
- Md Abu Sayed🇧🇩Chattagram Maa-O-Shishu Hospital Medical College
- Durjoy Acharjee🇧🇩Dhaka Medical College and Hospital
- Ali Saad Al‐Shammari🇮🇶University of Baghdad
- Mohd Turzo Rahman🇺🇸Flushing Hospital Medical Center
- Sakib Abrar🇧🇩Dhaka Medical College and Hospital
- Ta-Seen Bin Jamil🇧🇩Dhaka Medical College and Hospital
- Malaika Taseen
- Suborna Biswas🇧🇩Shaheed Suhrawardy Medical College
- Sumaya Khan Mifty🇧🇩Dhaka Medical College and Hospital
- Sajjad Ghanim Al-Badri🇮🇶University of Baghdad
- Avijit Debnath🇧🇩Jalalabad Ragib Rabeya Medical College
- Md. Sarowar Hossain
- Mst. Mahmuda Akter
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Cardiovascular disease remains the leading cause of mortality worldwide, with residual cardiovascular (CVS) risk remaining high despite pharmacological interventions. Cholesteryl ester transfer protein (CETP) inhibitors have shown promise in improving lipid profiles, but their comparative effectiveness in reducing CVS outcomes remains unclear. This network meta-analysis and network meta-regression aimed to evaluate the comparative effectiveness of CETP inhibitors (Evacetrapib, Anacetrapib, Dalcetrapib, and Torcetrapib) on CVS outcomes, including CVS mortality, all-cause mortality, major adverse cardiovascular events, myocardial infarction, need for revascularization, and stroke.
Methods
A Bayesian network meta-analysis was conducted, incorporating data from 10 randomized controlled trials with 84,134 patients diagnosed with cardiovascular disease or at high risk. We compared various CETP inhibitors for their effectiveness in reducing CVS events. Network meta-regression was used to assess the impact of covariates such as age, sex, and baseline lipid levels.
Results
Evacetrapib ranked highest for CVS mortality (relative risk [RR]: 0.92, 95% credible interval [CrI]: 0.39-1.87; Surface Under the Cumulative Ranking Curve [SUCRA]: 71.91%) and Anacetrapib for major adverse cardiovascular events (RR: 0.40, 95% CrI: 0.07-1.06; SUCRA: 84.25%). Dalcetrapib showed favorable effects on all-cause mortality (RR: 0.72, 95% CrI: 0.16-1.42; SUCRA: 67.51%) and stroke (RR: 0.75, 95% CrI: 0.41-1.26; SUCRA: 83.03%). Anacetrapib had the highest rank in reducing myocardial infarction (RR: 0.83, 95% CrI: 0.46-1.15; SUCRA: 86.06%).
Conclusions
This analysis suggests that Evacetrapib and Anacetrapib are the most effective CETP inhibitors for improving CVS outcomes, with Dalcetrapib showing beneficial effects in certain outcomes. Further studies are needed to confirm these findings.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.